Health Utilities to Inform Cancer Drug Funding Decision
Health Utilities (HUs) measure patient preferences and can be used to monitor quality-of-life (QoL) and calculate quality-adjusted life years (QALYs), which are used in economic evaluations assessing treatment interventions. HUs are typically measured in clinical trials, however, patients enrolled in clinical trials are often not representative of the general population or patients actually being treated for specific cancers.
We will use the Interactive Symptom Assessment and Collection “ISAAC” platform developed by OH(CCO) to administer EQ-5D-5L, a standardized health-related QoL instrument, to patients in Ontario receiving systemic therapy. Using collected data, we will:(1) directly measure HUs of patients receiving publicly reimbursed systemic therapy;(2) compare population-based real-world HUs with literature-based HUs from previous trials; and (3) compare QALYs calculated using population-based real-world HUs with trial-based QALYs calculated using trial-based HUs.
The collection of population-based real-world HUs and the calculation of real-world QALYs will enable the evaluation of the real-world cost effectiveness/cost-utility of funded cancer drugs. This will promote system sustainability allowing for monitoring and potential reassessment of publicly funded cancer therapies.